Crossmark Global Holdings’s ANI Pharmaceuticals ANIP Stock Holding History

Crossmark Global Holdings’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,160	Closed	-$257K	–	1272
2019 Q4	$257K	Buy	+4,160	New	+$276K	0.01%	1200
2018 Q3	–	Sell	-3,520	Closed	-$235K	–	1592
2018 Q2	$235K	Buy	+3,520	New	+$220K	0.01%	1460
2018 Q1	–	Sell	-3,360	Closed	-$217K	–	1579
2017 Q4	$217K	Sell	3,360 -940	-22%	-$58.5K	0.01%	1547
2017 Q3	$226K	Buy	+4,300	New	+$205K	0.01%	1498
2016 Q3	$226K	Buy	+4,300	New	+$269K	0.01%	1498

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Crossmark Global Holdings's ANIP Position: Q1 2020 in Review

Crossmark Global Holdings sold out of ANI Pharmaceuticals (ANIP) in Q1 2020, closing a stake of 4,160 shares — an estimated $257K sold.

Crossmark Global Holdings first reported a position in ANIP in Q3 2016 and held it in 5 quarters. The position peaked at $257K in Q4 2019. 140 funds tracked by Wall St. Rank hold ANIP as of Q1 2020.

Crossmark Global Holdings reported no remaining ANI Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Crossmark Global Holdings sold 4,160 ANI Pharmaceuticals shares in Q1 2020, an estimated $257K.
Crossmark Global Holdings first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 5 quarters.
Crossmark Global Holdings's ANI Pharmaceuticals position peaked at $257K in Q4 2019.
140 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2020.

Based on Crossmark Global Holdings's 13F filing for Q1 2020, filed 28 Apr 2020.